Argo Biopharma Doses First Patient in BW-41012 Trial
SHANGHAI, China & NEW YORK, July 20, 2026 Argo Biopharma has announced the successful dosing of the first participant...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SHANGHAI, China & NEW YORK, July 20, 2026 Argo Biopharma has announced the successful dosing of the first participant...
NEW ORLEANS, February 3, 2026 — Kandu, Inc., a healthcare technology company specializing in brain–computer interface (BCI)–enabled stroke recovery...
CHAPEL HILL, N.C., February 3, 2026 — SonoVascular, Inc., a clinical-stage medical device company focused on improving treatment for...
